Rezolute (RZLT) Competitors

Rezolute logo
$3.58 -0.07 (-1.92%)
Closing price 04:00 PM Eastern
Extended Trading
$3.52 -0.06 (-1.70%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RZLT vs. RARE, NUVB, DMRA, KARD, and ALVO

Should you buy Rezolute stock or one of its competitors? Rezolute's main competitors and comparable companies include Ultragenyx Pharmaceutical (RARE), Nuvation Bio (NUVB), Damora Therapeutics, Inc. Common Stock (DMRA), Kardigan (KARD), and Alvotech (ALVO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rezolute compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Rezolute has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Rezolute is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ultragenyx Pharmaceutical$673M2.41-$575M-$5.19N/A
RezoluteN/AN/A-$77.59M-$0.76N/A

Ultragenyx Pharmaceutical has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Rezolute has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market.

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 15.1% of Rezolute shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Rezolute had 10 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 17 mentions for Rezolute and 7 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 0.62 beat Rezolute's score of 0.04 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ultragenyx Pharmaceutical
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Rezolute
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ultragenyx Pharmaceutical presently has a consensus target price of $29.79, suggesting a potential upside of 87.36%. Rezolute has a consensus target price of $11.22, suggesting a potential upside of 213.47%. Given Rezolute's stronger consensus rating and higher probable upside, analysts clearly believe Rezolute is more favorable than Ultragenyx Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ultragenyx Pharmaceutical
1 Sell rating(s)
11 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.45
Rezolute
2 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.71

Rezolute has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -71.78%. Ultragenyx Pharmaceutical's return on equity of 0.00% beat Rezolute's return on equity.

Company Net Margins Return on Equity Return on Assets
Ultragenyx Pharmaceutical-71.78% N/A -39.70%
Rezolute N/A -72.24%-65.90%

Summary

Rezolute beats Ultragenyx Pharmaceutical on 9 of the 15 factors compared between the two stocks.

How does Rezolute compare to Nuvation Bio?

Rezolute (NASDAQ:RZLT) and Nuvation Bio (NYSE:NUVB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Rezolute has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market.

Rezolute presently has a consensus price target of $11.22, suggesting a potential upside of 213.47%. Nuvation Bio has a consensus price target of $12.89, suggesting a potential upside of 233.13%. Given Nuvation Bio's higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Rezolute.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rezolute
2 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.71
Nuvation Bio
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67

83.0% of Rezolute shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 15.1% of Rezolute shares are owned by insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Rezolute has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RezoluteN/AN/A-$77.59M-$0.76N/A
Nuvation Bio$62.90M21.71-$204.63M-$0.40N/A

In the previous week, Rezolute had 13 more articles in the media than Nuvation Bio. MarketBeat recorded 17 mentions for Rezolute and 4 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.14 beat Rezolute's score of 0.04 indicating that Nuvation Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rezolute
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nuvation Bio
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Rezolute has a net margin of 0.00% compared to Nuvation Bio's net margin of -67.38%. Nuvation Bio's return on equity of -45.69% beat Rezolute's return on equity.

Company Net Margins Return on Equity Return on Assets
RezoluteN/A -72.24% -65.90%
Nuvation Bio -67.38%-45.69%-18.54%

Summary

Nuvation Bio beats Rezolute on 8 of the 14 factors compared between the two stocks.

How does Rezolute compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Damora Therapeutics, Inc. Common StockN/AN/A-$209.84M-$1.41N/A
RezoluteN/AN/A-$77.59M-$0.76N/A

Damora Therapeutics, Inc. Common Stock has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Rezolute has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Comparatively, 15.1% of Rezolute shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Damora Therapeutics, Inc. Common Stock presently has a consensus target price of $46.38, suggesting a potential upside of 106.11%. Rezolute has a consensus target price of $11.22, suggesting a potential upside of 213.47%. Given Rezolute's higher possible upside, analysts plainly believe Rezolute is more favorable than Damora Therapeutics, Inc. Common Stock.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Damora Therapeutics, Inc. Common Stock
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
3 Strong Buy rating(s)
3.00
Rezolute
2 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.71

In the previous week, Rezolute had 14 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 17 mentions for Rezolute and 3 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.74 beat Rezolute's score of 0.04 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Damora Therapeutics, Inc. Common Stock
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Rezolute
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Rezolute's return on equity of -72.24% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company Net Margins Return on Equity Return on Assets
Damora Therapeutics, Inc. Common StockN/A -122.16% -62.32%
Rezolute N/A -72.24%-65.90%

Summary

Rezolute beats Damora Therapeutics, Inc. Common Stock on 8 of the 13 factors compared between the two stocks.

How does Rezolute compare to Kardigan?

Rezolute (NASDAQ:RZLT) and Kardigan (NASDAQ:KARD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Kardigan's return on equity of 0.00% beat Rezolute's return on equity.

Company Net Margins Return on Equity Return on Assets
RezoluteN/A -72.24% -65.90%
Kardigan N/A N/A N/A

83.0% of Rezolute shares are owned by institutional investors. 15.1% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Rezolute is trading at a lower price-to-earnings ratio than Kardigan, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RezoluteN/AN/A-$77.59M-$0.76N/A
KardiganN/AN/A-$191.94M-$2.88N/A

In the previous week, Kardigan had 3 more articles in the media than Rezolute. MarketBeat recorded 20 mentions for Kardigan and 17 mentions for Rezolute. Kardigan's average media sentiment score of 0.20 beat Rezolute's score of 0.04 indicating that Kardigan is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rezolute
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kardigan
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Rezolute currently has a consensus price target of $11.22, indicating a potential upside of 213.47%. Kardigan has a consensus price target of $41.00, indicating a potential upside of 219.07%. Given Kardigan's stronger consensus rating and higher possible upside, analysts plainly believe Kardigan is more favorable than Rezolute.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rezolute
2 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.71
Kardigan
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
2 Strong Buy rating(s)
2.90

Summary

Kardigan beats Rezolute on 7 of the 12 factors compared between the two stocks.

How does Rezolute compare to Alvotech?

Rezolute (NASDAQ:RZLT) and Alvotech (NASDAQ:ALVO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

83.0% of Rezolute shares are owned by institutional investors. 15.1% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Rezolute has a net margin of 0.00% compared to Alvotech's net margin of -50.62%. Alvotech's return on equity of 0.00% beat Rezolute's return on equity.

Company Net Margins Return on Equity Return on Assets
RezoluteN/A -72.24% -65.90%
Alvotech -50.62%N/A -11.94%

Rezolute presently has a consensus target price of $11.22, suggesting a potential upside of 213.47%. Alvotech has a consensus target price of $8.40, suggesting a potential upside of 90.48%. Given Rezolute's stronger consensus rating and higher probable upside, equities analysts plainly believe Rezolute is more favorable than Alvotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rezolute
2 Sell rating(s)
0 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.71
Alvotech
2 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.43

Alvotech has higher revenue and earnings than Rezolute. Alvotech is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RezoluteN/AN/A-$77.59M-$0.76N/A
Alvotech$588.90M2.26$27.92M-$0.82N/A

Rezolute has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

In the previous week, Alvotech had 10 more articles in the media than Rezolute. MarketBeat recorded 27 mentions for Alvotech and 17 mentions for Rezolute. Alvotech's average media sentiment score of 0.19 beat Rezolute's score of 0.04 indicating that Alvotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rezolute
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alvotech
4 Very Positive mention(s)
2 Positive mention(s)
16 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral

Summary

Rezolute beats Alvotech on 8 of the 14 factors compared between the two stocks.

Get Rezolute News Delivered to You Automatically

Sign up to receive the latest news and ratings for RZLT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RZLT vs. The Competition

MetricRezoluteBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$374.34M$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E RatioN/A26.5632.9627.39
Price / SalesN/A16.058.595.73
Price / CashN/A26.3721.9322.50
Price / Book4.024.074.403.70
Net Income-$77.59M-$22.86M$3.52B$392.17M
7 Day Performance-7.49%-7.26%-5.34%-4.53%
1 Month PerformanceN/A-4.96%-3.61%-5.86%
1 Year Performance-63.73%-2.87%0.01%-7.78%

Rezolute Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RZLT
Rezolute
2.8354 of 5 stars
$3.58
-1.9%
$11.22
+213.5%
-63.0%$374.34MN/AN/A58
RARE
Ultragenyx Pharmaceutical
2.7651 of 5 stars
$16.13
-1.7%
$29.79
+84.7%
-51.4%$1.59B$673MN/A1,371
NUVB
Nuvation Bio
2.9224 of 5 stars
$4.29
-1.5%
$12.89
+200.8%
-17.8%$1.50B$62.90MN/A310
DMRA
Damora Therapeutics, Inc. Common Stock
3.4211 of 5 stars
$24.34
+1.1%
$46.38
+90.5%
-19.5%$1.50BN/AN/A40
KARD
Kardigan
3.0573 of 5 stars
$15.91
+4.8%
$41.13
+158.5%
N/A$1.49BN/AN/A241

Related Companies and Tools


This page (NASDAQ:RZLT) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners